% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koerber:127605,
      author       = {S. A. Koerber$^*$ and C. Schoneweg$^*$ and A. Slynko$^*$
                      and D. Krug$^*$ and M. F. Haefner$^*$ and K. Herfarth$^*$
                      and J. Debus$^*$ and F. Sterzing$^*$ and M. von Knebel
                      Doeberitz$^*$ and E.-S. Prigge$^*$ and M. Reuschenbach$^*$},
      title        = {{I}nfluence of human papillomavirus and p16({INK}4a) on
                      treatment outcome of patients with anal cancer.},
      journal      = {Radiotherapy and oncology},
      volume       = {113},
      number       = {3},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2017-03628},
      pages        = {331 - 336},
      year         = {2014},
      abstract     = {The purpose of this study was to evaluate HPV-DNA and
                      p16(INK4a) (p16) expression as prognostic markers for
                      outcome in patients with anal cancer.From January 2000 to
                      December 2011 a cohort of 105 anal cancer patients was
                      treated with definitive chemoradiation at our institution.
                      Tumor biopsies from 90 patients were analyzed for HPV-DNA by
                      polymerase chain reaction and for p16 expression by
                      immunohistochemistry.Median follow-up was 48.6months (range
                      2.8-169.1months). HPV-DNA or p16-expression was found in 75
                      anal cancers each $(83.3\%),$ concordance was detectable in
                      70 tumors $(77.8\%).$ Significantly improved overall
                      survival (OS) $[77.1\%$ vs. $51.4\%,$ p=0.005],
                      progression-free survival (PFS) $[64.0\%$ vs. $35.0\%,$
                      p<0.001] and improved local control $[81.0\%$ vs. $55.9\%,$
                      p=0.023] was found for concomitant HPV- and p16-positive
                      anal carcinomas (cHPPAC) in univariate analysis.
                      Multivariate analysis showed better OS [p=0.015] and PFS
                      [p=0.002] for cHPPAC.The combination of HPV-DNA and p16 can
                      be used as an independent prognostic parameter in anal
                      cancer patients.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals) / Cyclin-Dependent Kinase
                      Inhibitor p16 (NLM Chemicals)},
      cin          = {E050 / C060 / G105},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G105-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25465729},
      doi          = {10.1016/j.radonc.2014.11.013},
      url          = {https://inrepo02.dkfz.de/record/127605},
}